Clinical Approaches to the Diagnosis and Treatment of Vascular Anomalies | Journal CME Article-Journal CME Article: Clinical Approaches to the Diagnosis and Treatment of Vascular Anomalies (Article)

Journal CME Article: Clinical Approaches to the Diagnosis and Treatment of Vascular Anomalies (Article)

Pdf Summary

This article reviews the modern diagnosis and treatment of vascular anomalies using the ISSVA classification, which separates lesions into vascular tumors and vascular malformations. Vascular tumors, such as infantile hemangiomas, typically appear after birth, grow rapidly, and may involute spontaneously. Vascular malformations are structural defects present at birth, grow proportionally with the child, and do not regress.<br /><br />The authors emphasize that accurate classification is essential because misdiagnosis has historically led to inappropriate treatment. They outline the epidemiology, noting an overall prevalence of about 4.5%, with infantile hemangioma as the most common benign tumor of infancy. Clinical presentation varies widely, from harmless birthmarks to lesions causing bleeding, pain, disfigurement, functional impairment, or even life-threatening complications such as hemorrhage and heart failure.<br /><br />A major theme is molecular pathophysiology. Many anomalies are driven by somatic or germline mutations affecting the PI3K/AKT/mTOR and RAS/MAPK pathways, often through a two-hit mechanism. These discoveries have enabled targeted therapies and better genetic counseling. The article also describes the role of next-generation sequencing and tissue-based genetic testing in refining diagnosis and guiding treatment.<br /><br />Diagnosis relies on history and physical examination, with imaging used to define lesion extent and flow characteristics. Doppler ultrasound and MRI are key tools for distinguishing high-flow lesions, such as AVMs, from slow-flow lesions, such as venous and lymphatic malformations.<br /><br />Management is individualized and multidisciplinary, combining observation, medications, laser therapy, sclerotherapy, embolization, and surgery. Propranolol remains first-line for complicated infantile hemangiomas, while sirolimus is useful for complex lymphatic malformations and PI3K-related disorders. The article concludes that coordinated care and biologically informed treatment strategies are essential for improving outcomes.

Keywords

vascular anomalies

ISSVA classification

infantile hemangioma

vascular malformations

PI3K/AKT/mTOR pathway

RAS/MAPK pathway

next-generation sequencing

Doppler ultrasound

MRI imaging

sirolimus